|
Originally published In Press as doi:10.1074/jbc.C100381200 on September 25, 2001
J. Biol. Chem., Vol. 276, Issue 45, 42057-42062, November 9, 2001
p53 Targets Chromatin Structure Alteration to Repress
-Fetoprotein Gene Expression*
Stacey K.
Ogden §,
Kathleen C.
Lee§¶,
Kara
Wernke-Dollries ,
Sabrina A.
Stratton ,
Bruce
Aronow**, and
Michelle Craig
Barton  
From the Department of Molecular Genetics,
Biochemistry and Microbiology, University of Cincinnati and
** Children's Hospital Research Foundation, Cincinnati, Ohio
45267 and the Department of Biochemistry and Molecular
Biology, University of Texas M. D. Anderson Cancer Center,
Houston, Texas 77030
Received for publication, July 6, 2001, and in revised form, September 12, 2001
 |
ABSTRACT |
Many of the functions ascribed to p53 tumor
suppressor protein are mediated through transcription regulation. We
have shown that p53 represses hepatic-specific -fetoprotein (AFP)
gene expression by direct interaction with a composite HNF-3/p53 DNA
binding element. Using solid-phase, chromatin-assembled AFP DNA
templates and analysis of chromatin structure and transcription
in vitro, we find that p53 binds DNA and alters chromatin
structure at the AFP core promoter to regulate transcription. Chromatin
assembled in the presence of hepatoma extracts is activated for AFP
transcription with an open, accessible core promoter structure. Distal
( 850) binding of p53 during chromatin assembly, but not
post-assembly, reverses transcription activation concomitant with
promoter inaccessibility to restriction enzyme digestion. Inhibition of
histone deacetylase activity by trichostatin-A (TSA) addition, prior to
and during chromatin assembly, activated chromatin transcription
in parallel with increased core promoter accessibility.
Chromatin immunoprecipitation analyses showed increased H3 and
H4 acetylated histones at the core promoter in the presence of TSA,
while histone acetylation remained unchanged at the site of distal p53
binding. Our data reveal that p53 targets chromatin structure
alteration at the core promoter, independently of effects on histone
acetylation, to establish repressed AFP gene expression.
 |
INTRODUCTION |
The tumor suppressor protein p53 plays central roles in the
regulation of cell growth, cell cycle arrest, and apoptosis. It is
activated in response to a variety of DNA damaging agents and has been
shown to interact with a number of cellular proteins of both mammalian
and viral origins. In general, the functional consequence of p53 DNA
binding is transcription activation of target genes with role(s) in
cellular stress response, as well as certain developmental pathways
(reviewed in Refs. 1-5). More recently, however, examples of
p53-mediated transcription repression through sequence-specific DNA
binding have been reported (6-9).
We have established that p53 binds within the
AFP1 distal developmental
repressor region, displacing bound trans-activator HNF-3
(FoxA) protein, and contributes to post-natal, tissue-specific repression of AFP (6). AFP is normally expressed at high levels in the
liver of the developing fetus and silenced after birth. Adult
expression of AFP is monitored as a tumor marker: aberrant reactivation
occurs in up to 85% of all hepatocellular carcinoma cases (reviewed in
Ref. 10).
In this study, we find that p53 binds to DNA during chromatin structure
organization as an obligate step in transcription repression. DNA
binding of p53 mediates distal regulation of AFP transcription through
alteration of chromatin structure at the core promoter. The ability of
p53 to regulate nucleosome positioning at the core promoter is
independent of histone modification. We show that histone
hyperacetylation has direct consequences for core promoter chromatin
accessibility and gene activation. These effects are overridden by
addition of p53, which represses transcription by restricting chromatin
accessibility even in the presence of hyperacetylated histone H3 and H4
N-terminal tails at the core promoter.
 |
EXPERIMENTAL PROCEDURES |
Plasmids and Solid-phase DNA
Templates--
AFP/lacZ contains 3.8-kilobbase
pair upstream DNA including proximal and distal promoter and
enhancer I, fused to the coding region of -galactosidase (11).
DelA/lacZ is identical except that it contains a
10-base pair deletion in one p53 binding half-site between 850 and
840, as well as a 4-bp mutation in the other half-site. It was
constructed by polymerase chain reaction mutation of the
previously described AFP/mut5 template (6). Solid-phase AFP/lacZ and DelA/lacZ templates
were coupled to streptavidin-coated paramagnetic beads as described
previously (12). The chick adult -globin plasmid,
pUC18ABC/ 1, contains the entire promoter, coding sequence, and 3'
enhancer (13).
Protein Expression and Cellular Extracts--
Cell
extracts were prepared from HeLa and HepG2 (AFP-positive, ATCC catalog
number HB-8065) cells as described by Dignam et al. (14)
with minor modifications (6). All extracts contained total proteins in
concentrations of 5-10 mg/ml. Xenopus egg extract high
speed supernatant (HSS) was prepared as described previously (15).
Constitutively activated, recombinant p53 protein was expressed from
p53 30his as detailed previously (16).
Chromatin Assembly and in Vitro Transcription--
In
vitro chromatin assembly and transcription reactions were
performed as reported previously (12). When trichostatin-A (TSA, Sigma)
was added to inhibit endogenous histone deacetylases in the
Xenopus egg HSS, the 10 mM
Me2SO stock solution was diluted to the desired
final concentration and incubated with HSS on ice for 10 min prior to
bead/DNA addition and chromatin assembly. For post-chromatin assembly
additions, proteins were added after the 1-h chromatin assembly period
and incubated for an additional 30 min. Chick -globin DNA template
was added as a control for RNA recovery. Results were quantified by
ImageQuant analysis of scanned autoradiograms.
Restriction Enzyme Accessibility--
HincII
restriction enzyme accessibility experiments were performed as
described previously (17). All restriction enzyme digests were
run on a 2% agarose gel and Southern blotted. A 23-bp 32P-end-labeled oligomer corresponding to promoter sequence
at +4 to +26, 5'-CCCACTTCCAGCACTGCCTGCGG-3', was used as probe.
Acetylated Histones H3 and H4 Antibodies--
The N-terminal 24 amino acids of human N-acetyllysine modified (4, 9, 14, 18,
23) H3 and (5, 8, 12, 16, 20) H4 were synthesized as tetrameric
multiply antigenic peptides (MAP) by Research Genetics, Inc.
(Birmingham, AL). Non-acetyl immunoreactive antibodies were removed by
subtracting with a synthetic, N-terminal non-acetylated mixture of H3
or H4 peptides. Finally, antibodies were affinity purified using AcH3
and AcH4 MAP. Specificity was confirmed by Western blot analysis, under
standard conditions, of histones purified by sodium butyrate treatment
and fractionated by acid gel electrophoresis.
Chromatin Immunoprecipitation--
Chromatin
immunoprecipitation (ChIP) assays were performed on in vitro
chromatin assembled DNA templates. Protein-DNA complexes were
cross-linked by exposure to 1% formaldehyde (final concentration) for
10 min at room temperature, followed by 50 min on ice. These reactions
were diluted 3-fold in Xenopus egg extract buffer (12) and
mixed gently. The supernatant was removed after magnetic concentration, and bead/DNA was resuspended in 1× SM2 buffer (500 mM
sucrose, 80 mM KCl, 20 mM HEPES, pH 7.5, 3.5 mM ATP, 6 mM CaCl2) plus 1.5 units
of micrococcal nuclease (MNase, Roche Molecular Biochemicals) (12). A
5-min incubation with MNase digested cross-linked chromatin into
200-500-nucleotide size fragments, as determined empirically by
agarose gel electrophoresis and Southern blotting. After stopping digestions in 20 mM EDTA, 2 mM EGTA (final
concentration), 9 volumes of ChIP dilution buffer (16.7 mM
Tris-HCl, pH 8.1, 167 mM NaCl, 1.1% Triton X-100, 0.01%
SDS, 1.2 mM EDTA) were added to each sample. This diluted
sample of chromatin/protein/DNA fragments was removed as a supernatant
from the immobilized paramagnetic beads and divided among several
reaction tubes for incubation with control and specific antibodies as
described previously (18). The presence of immunoprecipitated
DNA sequences was determined by Southern blotting using a slot-blot
manifold for binding DNA to GeneScreen Plus membrane (Beckman Chemical
Co.). Hybridization with 32P-end-labeled, double-stranded
oligomers encompassing AFP/lacZ sequences from +4 to
+26 (promoter probe), from 860 to 830 (p53-binding site), and
random-primed labeled full-length template was performed as described
previously (17). Results were quantified by ImageQuant analysis
of scanned autoradiograms. Values are expressed as a ratio of bound to
input, corrected by comparison to no antibody and full-length template controls.
 |
RESULTS |
p53 Binding Mediates Transcriptional Repression and Chromatin
Structure Alteration--
We employed in vitro chromatin
assembly of solid-phase AFP DNA templates to reconstitute repression of
AFP transcription through a distal p53-regulatory element. We showed
previously that chromatin assembly by this method establishes
physiologically spaced nucleosomes over the entire DNA template and
renders in vitro transcription tissue-specific, in contrast
to nucleosome-free DNA (12, 17). These templates were either
transcribed for functional analysis or structurally analyzed for
promoter accessibility or histone modification status (Fig.
1A). Nucleosome assembly
silences AFP transcription compared with unassembled DNA templates
(Fig. 1B, lane 1, compared with -globin
transcripts). Addition of HepG2 extract, prepared from cultured human
hepatoma cells that express AFP, during chromatin assembly derepresses
and/or activates AFP transcription an average of 5-fold (lane
2). Titration of increasing amounts of recombinant p53, in
addition to HepG2 extract, during chromatin assembly represses AFP
chromatin transcription up to 3-fold (lanes 6 and
7). However, p53 introduced after chromatin structure was
established had no significant effect on transcription (p53post, average of 1.1-fold increase, lanes
3-5).

View larger version (63K):
[in this window]
[in a new window]
|
Fig. 1.
p53 represses AFP chromatin transcription
in vitro. A, solid-phase chromatin
assembly. Chromatin is assembled in the presence of proteins, extracts,
and/or buffer for 1 h prior to magnetic concentration, washing,
and removal of unbound proteins. Chromatin templates are then
transcribed or analyzed for chromatin structure accessibility.
B, transcription analysis of p53 added during chromatin
assembly or after chromatin assembly. 500 ng of
AFP/lacZ template DNA were incubated in buffer only
(lane 1) or with HepG2 extract (lanes 2-7) and 0 ( , lane 2), 150 ng (+, lane 3), 300 ng (++, lanes 4 and 6), or 450 ng
(+++, lanes 5 and 7) of p53 and
transcribed. p53 was added either prior to chromatin assembly
(lanes 6 and 7) or after chromatin assembly was
completed (lanes 3-5). Molecular weight standards
(MW) were radiolabeled x174 HaeIII digestion
reaction (Life Technologies, Inc.). -Globin serves as an RNA
recovery control.
|
|
We have utilized restriction enzyme accessibility to monitor changes in
promoter chromatin structure induced by p53 DNA binding (Fig.
2). HincII restriction
digestion at sites that flank the AFP promoter at 55 and +29, Fig.
2A, correlates with a core promoter region relatively free
of a bound nucleosome and open to transcription complex assembly (12,
17). Structural analysis mirrored the functional effects of p53
addition both during and post-chromatin assembly (Fig. 2B).
Compared with chromatin assembly in buffer only, HepG2 extract
established an open core promoter (lane 3 compared with
lane 2). Addition of p53 protein during chromatin assembly
revealed a dose-dependent chromatin closure (lanes
4-6, compared with lane 3). The core promoter
chromatin structure remained relatively inert to p53 protein addition
post-assembly (lanes 7 and 8). A quantitative
average of these data and similar experiments are graphed in Fig.
2C. Comparison of both transcription and chromatin structural consequences of p53 addition pre- and post-chromatin assembly support the view that p53 action is primarily at the level of
chromatin structure organization rather than targeting modification of
an established chromatin structure.

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 2.
p53 organizes chromatin structure.
A, core promoter accessibility assay. The core promoter of
AFP has HincII sites at 55 and +29. Digestion of chromatin
with HincII releases an 84-bp fragment only when both sites
are accessible. The ovals represent nucleosomes bound at the
AFP promoter: dashed ovals are nucleosomes that obstruct
enzyme digestion and, presumably, transcription factor binding.
B, restriction enzyme probing of chromatin structure.
HincII accessibility analysis was performed on
chromatin-assembled templates. Chromatin-free DNA (lane 1)
and chromatin-assembled DNA (lanes 2-8) were preincubated
with p53 (lanes 4, 5, and 6; 75, 150, and 300 ng, respectively), or p53 was added after assembly (lanes
7 and 8, 150 and 300 ng, respectively) in the presence
of HepG2 extract (lanes 3-8). Uncut DNA is present in
lane 9. C, graphic representation of
transcription activation and promoter accessibility. The quantitative
averages of at least two separate assays for p53-regulated
transcription (open boxes) and promoter accessibility
(shaded boxes), added prior to (pre) or after
(post) chromatin assembly, are compared with HepG2-activated
chromatin assembled in the absence of p53. Concentrations of p53 are
1×, 150 ng, and 2×, 300 ng.
|
|
The p53 DNA-binding site within the AFP upstream region ( 860/ 830,
Fig. 3A) fits the consensus
binding sequence for a p53 tetramer at the 5' half-site
(PuPuPuCA/TA/TGPyPyPy (19)). However, this p53 repressor element
has a 3' half-site following a 3-base pair nucleotide spacer that
deviates from consensus (PyPyPyCTAGPuPyPu). The influence of DNA
binding sequence on p53 conformation and function has been described
previously (20), but the specific way in which this response element
dictates p53 regulation of AFP is not known. Deletion and mutation of
the p53-binding site (DelA) abolishes both p53 and HNF-3 binding at
this site (data not shown). Consistent with lack of p53 binding,
repression of chromatin transcription (Fig. 3B) and
structure accessibility at the core promoter (Fig. 3C) are
lost.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 3.
DNA binding is required for p53
function. A, a mutated AFP template. The 860 to 830
sense strand of AFP is depicted with the p53-binding site (consensus 5'
half-site (solid line) and non-consensus 3' half-site
(dashed line)) marked above the normal DNA sequence
(AFP) and the HNF-3 site below mutated p53 sequence
(DelA). DelA lacks the nucleotides indicated by
hyphens and has altered bases in lowercase
letters. B, p53 binds to DNA to repress
transcription. AFP (lanes 1-5) and DelA
(lanes 6-9) bead-DNA were transcribed in vitro
as chromatin-free (lane 1) and -assembled (lanes
2-9) templates. Chromatin was assembled in the presence of buffer
(lanes 2 and 6), HepG2 extract (lanes
3-5 and 7-9), plus p53 protein (lanes 4 and 8, 150 ng; lanes 5 and 9, 300 ng).
C, p53 binds DNA to alter core promoter
accessibility. AFP (lanes 1-5) and DelA
templates (lanes 6-10) were incubated in buffer
(lanes 5 and 10) or chromatin assembled
(lanes 1-4 and 6-9) as described above. HepG2
extract (lanes 2-5 and 7-10) was supplemented
with 150 (+, lanes 3 and 8) and 300 (++, lanes 4 and 9) ng of p53 during
assembly. Southern blot analysis reveals relative HincII
accessibility of chromatin (84-bp HincII band).
|
|
Histone Modification Does Not Alter p53-mediated Restriction of
Promoter Accessibility--
Nucleosome positioning, which restricts
core promoter access to restriction enzymes and transcription
preinitiation complexes, may be affected by histone N-terminal tail
interactions with DNA. Chromatin composed of highly acetylated
histones, in general, may be more dynamic and readily activated for
transcription; whereas, the opposite may be true for underacetylated
nucleosomes. Multiple transcription factors interact with protein
complexes displaying intrinsic enzymatic activity, such as histone
acetyl transferases (HAT's) or histone deacetylases (HDAC's), and
target modification of chromatin by virtue of their DNA binding ability
(recently reviewed in Refs. 21-23). Several studies have shown
interactions between both HAT and HDAC complexes and p53, interactions
that may promote histone modification, p53 modification, or p53
stabilization (24-30). Our base-line study of histone modification at
the core promoter and the p53-binding site at 850 revealed no
significant variation in histone H3 acetylation between these regions,
in the presence or absence of p53. Four separate ChIP experiments were
performed and the percent of acetylated histone H3 present at these
regions averaged: at the core promoter, 27.8% ± 9.3 (in the absence
of p53) and 27.6% ± 9.2 (in the presence of p53); and at the
p53-binding site, 35.1% ± 5.7 ( p53) and 32.2% ± 5.9 (+p53).
Although there were no significant variances between histone
modification states localized at the core promoter or p53-binding site,
there were striking differences in acetylation states when the
equilibrium between acetylases and deacetylases was shifted by addition
of TSA to Xenopus egg extract in the absence of hepatoma proteins (Fig. 4). In response to
increasing concentration of TSA, nucleosomes present at the core
promoter region increased in both H3 and H4 acetylation 2-3-fold.
However, in the local region of p53 binding, histone modification was
maintained at a base-line level over the concentration range of TSA
(Fig. 4A). Somewhat surprisingly, the presence or absence of
p53 protein made little difference to the state of histone modification
at all levels of TSA. Thus, we find no evidence that p53 alone targets modification of histone tails at the p53-binding site or at the core
promoter.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 4.
p53-mediated repression of AFP transcription
occurs even in the presence of hyperacetylated histones at the core
promoter. A, addition of TSA promotes hyperacetylation
of histones H3 and H4 at the AFP core promoter but not at the
p53-binding site. ChIP analyses of H3 (white bars) and H4
(shaded bars) acetylated histone populations present at the
core promoter region (open bars) and the p53 binding region
(hatched bars) were performed on in vitro
chromatin-assembled AFP templates in the presence (+, 300 ng) or absence ( ) of p53. Chromatin was assembled in
Xenopus egg extract, incubated in increasing amounts of TSA:
none, 10 nM, 100 nM, and 3 µM.
Histone acetylation levels were expressed as a ratio compared with
base-line values determined in the absence of TSA (see
"Results"). These TSA titration experiments were performed
twice, thus S.D. values are not presented. B, histone
hyperacetylation leads directly to derepressed chromatin transcription
that is silenced by p53 addition. Xenopus egg extract
incubated in the presence of 0, 10 nM, 100 nM,
3 µM, and 10 µM TSA was used to assemble
AFP bead-DNA into chromatin and transcribed (lanes 1-5,
respectively). p53 (300 ng) was added during chromatin assembly
(lanes 6 and 7) in egg extract incubated in the
presence of 0 (lane 6) or 3 µM TSA (lane
7). RNA recovery control primer extension analysis of added
-globin DNA template was performed separately on these reactions
(small gel inset). C, p53-mediated silencing of
TSA-derepressed transcription requires DNA binding. DelA bead-DNA was
assembled in chromatin as described above, using Xenopus egg
extract incubated in the presence of 0 (lane 1), 3 µM (lanes 2, 4, and 5),
and 10 µM (lane 3). p53 protein was added
during chromatin assembly (lane 4, 150 ng; and lane
5, 300 ng). D, p53 mediates core promoter closure even
in the presence of hyperacetylated histones. HincII
restriction accessibility was performed on AFP templates in the absence
of chromatin assembly (lane 1) or when assembled into
chromatin (lanes 2-5). Chromatin was assembled in
Xenopus egg extract incubated in no TSA (lane 2)
or 10 µM TSA (lanes 3-5). Addition of p53
(+, 150 ng, lane 4; ++, 300 ng,
lane 5) altered chromatin accessibility to HincII
enzyme.
|
|
The specific increases in histone H3 and H4 acetylation at the core
promoter led directly to derepression of transcription in the absence
of any exogenous activator proteins (Fig. 4B). Functionally,
the 2-3-fold changes in histone acetylation at the core promoter
mediated a 2-fold increase in transcription of chromatin assembled in
Xenopus egg extract treated with TSA (lanes
1-5). The increase in transcription was not dependent on the
p53/HNF3-binding site, as similar transcription of the DelA AFP
template in TSA-treated egg extract also showed transcription increase
with increasing TSA (Fig. 4C, lanes 2 and
3 compared with lane 1).
Despite the presence of highly acetylated histones at the core
promoter, p53 was able to repress transcription fully when added during
chromatin assembly (Fig. 4B, lane 7 compared with lanes 1 and 6). The ability to repress chromatin
transcription was absolutely dependent on DNA binding of p53 as the
DelA AFP template remained transcriptionally active in the presence of p53 (Fig. 4C, lanes 4 and 5).
Restriction accessibility analysis of core promoter chromatin (Fig.
4D) showed a parallel increase of 2-fold in the presence of
TSA (lane 3), and repression to base-line levels in the
presence of added p53 (lanes 4 and 5), both in
parallel with effects on transcription function (Fig. 4B).
The ability of p53 to modify nucleosome/DNA interactions at the core
promoter, resulting in chromatin structure closure and repression of
transcription, is not dependent on tissue-specific factors or targeted
modification of histone acetylation and occurs even in the presence of
highly acetylated nucleosomes.
 |
DISCUSSION |
During hepatic development and post-natal silencing of AFP
expression, specific changes in chromatin structure of the AFP gene
occur, which likely play a role in regulation (31, 32). Our present
study reveals that the functional outcome of p53 DNA binding within the
AFP distal repressor region is dictated by chromatin structure
organization. Chromatin structure can influence transcription
regulation by obstructing transcription factor access to DNA or by
facilitating interactions between distal regulatory factors and
proximal promoter elements to repress or activate transcription
(33-38). Our in vitro chromatin transcription system recapitulates distal regulation of AFP transcription by p53 bound to
DNA 850 base pairs 5' of the transcription start site within the AFP
developmental repressor domain. As best studied in
Drosphila, distal repressors, like distal enhancers, are
essential in regulation of development and differentiation (39).
Proteins that interact with DNA regulatory elements dictate chromatin
activation or repression, as well as the consequences of p53
regulation. AFP chromatin is derepressed or activated in the presence
of hepatoma extract, but remains transcriptionally repressed when
assembled in HeLa extract (17). As shown here, p53 mediates repression
of hepatoma-activated chromatin, but in the presence of HeLa extract a
low level of transcription activation is observed instead (40). Thus,
the interpretation of p53 protein interaction with DNA, whether
activating or repressing chromatin structure, is influenced by multiple
trans-acting factors. The timing of these interactions
relative to chromatin assembly is important as well. We find that p53
lacks the ability to alter an established, activated chromatin
structure. HNF-3 (FoxA) protein, present in the HepG2 extract, mediates
core accessibility to HincII restriction enzyme and basal
transcription factors in chromatin transcription (17). Zaret and
co-workers (41, 42) established that HNF-3 is an architectural
transcription factor that can position nucleosomes along the albumin
enhancer, rendering it competent for later trans-activator
binding. Thus, HNF-3 acts as primary effector of chromatin modification
and derepression, and this established chromatin structure cannot be
altered by post-assembly addition of p53. Previous investigations
revealed that p53 binding to DNA induces considerable bending and
twisting at its binding site, and the inherent
sequence-dependent form that DNA assumes greatly affects
p53 DNA binding properties (43). The manipulation of DNA and chromatin
structure by proteins such as HNF-3 and/or p53 may establish a
requisite order of transcription factor binding to induce specific
chromatin-repressed or -activated forms. Studies of Swi5p-mediated
recruitment of Swi/Snf and SAGA complexes at the yeast HO
endonuclease gene promoter (44), as well as temporal recruitment of
chromatin remodeling and histone modifying complexes by nuclear
receptors (45), support the idea that only specific transcription
factors can interact with chromatin to initiate a series of regulatory
steps. This temporal order is likely influenced by flanking DNA
sequence, the complexity of the regulatory element(s), and interacting proteins.
Our results showing that p53 cannot bind and repress a previously
activated chromatin template are in contrast to p53 action at a
chromatin-repressed (assembled in buffer) p21 gene template (46). In this case, p53 can bind to chromatin and target p300 to
acetylate histone tails at a p53-binding site, which then spreads distally to the core promoter. Together, p53 and p300 activate transcription of chromatin-repressed p21 gene templates. The
ability of p53 protein to target histone modification was also
suggested by previous studies. Transcription repression of the
MAP4 gene is correlated with p53-mediated histone
deacetylation and promoter-localized histone modification in cultured
cells (24). Our studies of histone modification revealed little change
in histone acetylation mediated by p53 addition during chromatin
assembly in untreated Xenopus egg extract. When the
equilibrium between histone acetylase and deacetylase activities was
shifted toward acetylation by TSA addition, the p53-binding site region
was maintained in a state of reduced acetylation, even in the absence
of exogenous p53, compared with the core promoter. We propose that
local histone modification at the AFP repressive p53-binding site is
maintained by multiple protein
complexes.2 Regional,
regulated shifts in acetylation/deacetylation equilibria may be
revealed by disruption of histone acetylase or deacetylase activities
(47), which exist endogenously in Xenopus egg extract.
Despite increased histone acetylation, p53 regulates chromatin
structure alteration that creates inaccessibility at the AFP core
promoter. The ability of p53 to modify chromatin structure at the core
promoter is not dependent on the presence of hepatoma-specific factors
and is inhibited when tissue-specific factors have previously established active chromatin. Our studies reveal a hierarchy of transcription regulation by p53 in which distal alterations in chromatin structure rather than local modification of histone tails
play a key role in repressing AFP gene expression. It will be of great
interest to compare other p53-repressed and -activated genes and
establish whether the interpretation of p53 induction as a
transcription activation or repression signal is dictated by DNA
regulatory site complexity, interacting proteins, and consequent chromatin structure alteration.
 |
ACKNOWLEDGEMENTS |
We thank C. Florio for techanical assistance
with ChIP protocols and antibody characterization and A. J. Crowe
for generous help in methodology, insightful discussions, and critical reading.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grant (NIH) GM53683 (to M. C. B.), by NIH predoctoral
training Grant T32 CA59268, and by a Ryan Foundation Fellowship
(provided support for S. K. O.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Equally contributing authors.
¶
Current address: Dept. of Molecular Biology and Genetics,
Cornell University, 467 Biotechnology Bldg., Ithaca, NY 14853.

To whom correspondence should be addressed: Dept. of
Biochemistry and Molecular Biology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 117, Houston, TX 77030. E-mail:
mbarton@odin.mdacc.tmc.edu.
Published, JBC Papers in Press, September 25, 2001, DOI 10.1074/jbc.C100381200
2
S. Ogden and M. Barton, unpublished results.
 |
ABBREVIATIONS |
The abbreviations used are:
AFP, -fetoprotein;
TSA, trichostatin-A;
HSS, high speed supernatant;
ChIP, chromatin immunoprecipitation;
HAT, histone acetyl transferase;
HDAC, histone deacetylase;
MAP, multiply antigenic peptide;
MNase, micrococcal nuclease;
bp, base pair(s);
Pu, purine;
Py, pyrimidine.
 |
REFERENCES |
| 1.
|
Weiss, J.,
Heine, M.,
Arden, K. C.,
Korner, B.,
Pilch, H.,
Herbst, R. A.,
and Jung, E. G.
(1995)
Recent Results Cancer Res.
139,
137-154[Medline]
[Order article via Infotrieve]
|
| 2.
|
Greenblatt, M. S.,
Bennett, W. P.,
Hollstein, M.,
and Harris, C. C.
(1994)
Cancer Res.
54,
4855-4878[Free Full Text]
|
| 3.
|
Lane, D. P.
(1994)
Int. J. Cancer
57,
623-627[Medline]
[Order article via Infotrieve]
|
| 4.
|
Kastan, M. B.,
Canman, C. E.,
and Leonard, C. J.
(1995)
Cancer Metastasis Rev.
14,
3-15[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Ko, L. J.,
and Prives, C.
(1996)
Genes Dev.
10,
1054-1072[Free Full Text]
|
| 6.
|
Lee, K. C.,
Crowe, A. J.,
and Barton, M. C.
(1999)
Mol. Cell. Biol.
19,
1279-1288[Abstract/Free Full Text]
|
| 7.
|
Ori, A.,
Zauberman, A.,
Doitsch, G.,
Paran, N.,
Oren, M.,
and Shaul, Y.
(1998)
EMBO J.
17,
544-553[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Budhram-Mahadeo, V.,
Morris, P. J.,
Smith, M. D.,
Midgley, C. A.,
Boxer, L. M.,
and Latchman, D. S.
(1999)
J. Biol. Chem.
274,
15237-15244[Abstract/Free Full Text]
|
| 9.
|
Johnson, R. A.,
Ince, T. A.,
and Scotto, K. W.
(2001)
J. Biol. Chem.
276,
27716-27720[Abstract/Free Full Text]
|
| 10.
|
Tilghman, S. M.
(1985)
Oxf. Surv. Eukaryotic Genes
2,
160-206[Medline]
[Order article via Infotrieve]
|
| 11.
|
Spear, B. T.,
Longley, T.,
Moulder, S.,
Wang, S. L.,
and Peterson, M. L.
(1995)
DNA Cell Biol.
14,
635-642[Medline]
[Order article via Infotrieve]
|
| 12.
|
Crowe, A. J.,
and Barton, M. C.
(1999)
Methods Companion Methods Enzymol.
17,
173-187
|
| 13.
|
Emerson, B. M.,
Nickol, J. M.,
and Fong, T. C.
(1989)
Cell
57,
1189-1200[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Dignam, J. D.,
Lebovitz, R. M.,
and Roeder, R. G.
(1983)
Nucleic Acids Res.
11,
1475-1489[Abstract/Free Full Text]
|
| 15.
|
Barton, M. C.,
and Emerson, B. M.
(1996)
Methods Enzymol.
274,
299-312[Medline]
[Order article via Infotrieve]
|
| 16.
|
Zaret, K. S.,
and Stevens, K.
(1995)
Protein Expression Purif.
6,
821-825[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Crowe, A. J.,
Sang, L.,
Li, K. K.,
Lee, K. C.,
Spear, B. T.,
and Barton, M. C.
(1999)
J. Biol. Chem.
274,
25113-25120[Abstract/Free Full Text]
|
| 18.
|
Kuo, M. H.,
and Allis, C. D.
(1999)
Methods Companion Methods Enzymol.
19,
425-433
|
| 19.
|
El-Deiry, W. S.,
Kern, S. E.,
Pietenpol, J. A.,
Kinzler, K. W.,
and Vogelstein, B.
(1992)
Nat. Genet.
1,
45-49[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Thornborrow, E. C.,
and Manfredi, J. J.
(1999)
J. Biol. Chem.
274,
33747-33756[Abstract/Free Full Text]
|
| 21.
|
Mizzen, C.,
Kuo, M. H.,
Smith, E.,
Brownell, J.,
Zhou, J.,
Ohba, R.,
Wei, Y.,
Monaco, L.,
Sassone-Corsi, P.,
and Allis, C. D.
(1998)
Cold Spring Harbor Symp. Quant. Biol.
63,
469-481[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Howe, L.,
Brown, C. E.,
Lechner, T.,
and Workman, J. L.
(1999)
Crit. Rev. Eukaryot. Gene Expr.
9,
231-243[Medline]
[Order article via Infotrieve]
|
| 23.
|
Sterner, D. E.,
and Berger, S. L.
(2000)
Microbiol. Mol. Biol. Rev.
64,
435-459[Abstract/Free Full Text]
|
| 24.
|
Murphy, M.,
Ahn, J.,
Walker, K. K.,
Hoffman, W. H.,
Evans, R. M.,
Levine, A. J.,
and George, D. L.
(1999)
Genes Dev.
13,
2490-2501[Abstract/Free Full Text]
|
| 25.
|
Woods, D. B.,
and Vousden, K. H.
(2001)
Exp. Cell Res.
264,
56-66[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Koumenis, C.,
Alarcon, R.,
Hammond, E.,
Sutphin, P.,
Hoffman, W.,
Murphy, M.,
Derr, J.,
Taya, Y.,
Lowe, S. W.,
Kastan, M.,
and Giaccia, A.
(2001)
Mol. Cell. Biol.
21,
1297-1310[Abstract/Free Full Text]
|
| 27.
|
Liu, L.,
Scolnick, R. C.,
Trievel, H. B.,
Zhang, H. B.,
Marmorstein, R.,
Halazonetis, T. D.,
and Berger, S. L.
(1999)
Mol. Cell. Biol.
19,
1202-1209[Abstract/Free Full Text]
|
| 28.
|
Bayle, J. H.,
and Crabtree, G. R.
(1997)
Chem. Biol.
4,
885-888[Medline]
[Order article via Infotrieve]
|
| 29.
|
Gu, W.,
and Roeder, R. G.
(1997)
Cell
90,
595-606[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Zilfou, J. T.,
Hoffman, W. H.,
Sank, M.,
George, D. L.,
and Murphy, M.
(2001)
Mol. Cell. Biol.
21,
3974-3985[Abstract/Free Full Text]
|
| 31.
|
Chou, J. Y.,
and Wan, Y.-J. Y.
(1989)
Oxf. Surv. Eukaryot. Genes
6,
1-31[Medline]
[Order article via Infotrieve]
|
| 32.
|
Godbout, R.,
and Tilghman, S. M.
(1988)
Genes Dev.
2,
949-956[Abstract/Free Full Text]
|
| 33.
|
Schild, C.,
Claret, F.-X.,
Wahli, W.,
and Wolffe, A. P.
(1993)
EMBO J.
12,
423-433[Medline]
[Order article via Infotrieve]
|
| 34.
|
Wallrath, L. L.,
Lu, Q.,
Granok, H.,
and Elgin, S. C. R.
(1994)
Bioessays
16,
165-170[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Langst, G.,
Becker, P. B.,
and Grummt, I.
(1998)
EMBO J.
17,
3135-3145[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Agarwal, S.,
and Rao, A.
(1998)
Curr. Opin. Immunol.
10,
345-352[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Cai, H. N.,
Arnosti, D. N.,
and Levine, M.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
9309-9314[Abstract/Free Full Text]
|
| 38.
|
Wijgerde, M.,
Grosveld, F.,
and Fraser, P.
(1995)
Nature
377,
209-213[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Gray, S.,
and Levine, M.
(1996)
Curr. Opin. Cell Biol.
8,
358-364[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Ogden, S. K.,
Lee, K. C.,
and Barton, M. C.
(2000)
J. Biol. Chem.
275,
27806-27814[Abstract/Free Full Text]
|
| 41.
|
McPherson, C. E.,
Eun-Yong, S.,
Friedman, D. S.,
and Zaret, K. S.
(1993)
Cell
75,
387-398[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Shim, E. Y.,
Woodcock, C.,
and Zaret, K. S.
(1998)
Genes Dev.
12,
5-10[Abstract/Free Full Text]
|
| 43.
|
Nagaich, A. K.,
Zhurkin, V. B.,
Durell, S. R.,
Jernigan, R. L.,
Appella, E.,
and Harrington, R. E.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
1875-1880[Abstract/Free Full Text]
|
| 44.
|
Cosma, M. P.,
Tanaka, T.,
and Nasmyth, K.
(1999)
Cell
97,
299-311[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Dilworth, F. J.,
Fromental-Ramain, C.,
Yamamoto, K.,
and Chambon, P.
(2000)
Mol. Cell
6,
1049-1058[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Espinosa, J. M.,
and Emerson, B. M.
(2001)
Mol. Cell
8,
57-69[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Vogelauer, M.,
Wu, J.,
Suka, N.,
and Grunstein, M.
(2000)
Nature
408,
495-498[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. Van Bodegom, Z. Saifudeen, S. Dipp, S. Puri, B. S. Magenheimer, J. P. Calvet, and S. S. El-Dahr
The Polycystic Kidney Disease-1 Gene Is a Target for p53-mediated Transcriptional Repression
J. Biol. Chem.,
October 20, 2006;
281(42):
31234 - 31244.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-Y. Cho, Z. He, Y. Zhang, H. S. Choi, F. Zhu, B. Y. Choi, B. S. Kang, W.-Y. Ma, A. M. Bode, and Z. Dong
The p53 Protein Is a Novel Substrate of Ribosomal S6 Kinase 2 and a Critical Intermediary for Ribosomal S6 Kinase 2 and Histone H3 Interaction
Cancer Res.,
May 1, 2005;
65(9):
3596 - 3603.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. T. Nguyen, K. Cho, S. A. Stratton, and M. C. Barton
Transcription Factor Interactions and Chromatin Modifications Associated with p53-Mediated, Developmental Repression of the Alpha-Fetoprotein Gene
Mol. Cell. Biol.,
March 15, 2005;
25(6):
2147 - 2157.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Wilkinson, S. K. Ogden, S. A. Stratton, J. L. Piechan, T. T. Nguyen, G. A. Smulian, and M. C. Barton
A Direct Intersection between p53 and Transforming Growth Factor {beta} Pathways Targets Chromatin Modification and Transcription Repression of the {alpha}-Fetoprotein Gene
Mol. Cell. Biol.,
February 1, 2005;
25(3):
1200 - 1212.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Fan, J. R. Harrell, S. Dipp, Z. Saifudeen, and S. S. El-Dahr
A novel pathological role of p53 in kidney development revealed by gene-environment interactions
Am J Physiol Renal Physiol,
January 1, 2005;
288(1):
F98 - F107.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kataoka, P. Bonnefin, D. Vieyra, X. Feng, Y. Hara, Y. Miura, T. Joh, H. Nakabayashi, H. Vaziri, C. C. Harris, et al.
ING1 Represses Transcription by Direct DNA Binding and through Effects on p53
Cancer Res.,
September 15, 2003;
63(18):
5785 - 5792.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Marks, Z. Saifudeen, S. Dipp, and S. S. El-Dahr
Two Functionally Divergent p53-responsive Elements in the Rat Bradykinin B2 Receptor Promoter
J. Biol. Chem.,
September 5, 2003;
278(36):
34158 - 34166.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Wolcke, M. Reimann, M. Klumpp, T. Gohler, E. Kim, and W. Deppert
Analysis of p53 "Latency" and "Activation" by Fluorescence Correlation Spectroscopy: EVIDENCE FOR DIFFERENT MODES OF HIGH AFFINITY DNA BINDING
J. Biol. Chem.,
August 29, 2003;
278(35):
32587 - 32595.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|